JUPITER, Fla., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered functional input proteins for use in life sciences, food and nutrition, and industrial biotechnology applications utilizing its proprietary gene expression platforms, today announced that it will report its financial results for the sec ...

Third quarter revenue of $768 million, up 5.9%, and up 5.5% on an organic constant currency (OCC) basis.Net income of $226 million, up 2.5% as strong operating performance were partially offset by higher net interest expense in the current year and investment gain in the prior year.Adjusted EBITDA, a non-GAAP measure, of $429 million, up 7.2%, and up 8.8% on an OCC basis.Diluted GAAP earnings per share of $1.61, up 4.5%.Diluted adjusted EPS, a non-GAAP measure, of $1.72, up 3.0%.Pending AccuLynx acquisition ...

Core Insights - Virtu Financial, Inc. reported a strong financial performance for the third quarter of 2025, with total revenues increasing by 16.7% to $824.8 million compared to $706.8 million in the same period of 2024 [4][11] - The company declared a quarterly cash dividend of $0.24 per share, payable on December 15, 2025 [3] Financial Results - Total revenues for Q3 2025 reached $824.8 million, a 16.7% increase from $706.8 million in Q3 2024 [4] - Trading income, net, rose by 19.2% to $529.1 million compared to $444.0 million in the prior year [4] - Net income for the quarter was $149.1 million, up from $119.0 million in Q3 2024 [4][11] - Basic and diluted earnings per share were $0.86, compared to $0.65 and $0.64 for the same period in 2024 [5] Adjusted Financial Metrics - Adjusted Net Trading Income increased by 20.4% to $467.0 million for Q3 2025, compared to $388.0 million in Q3 2024 [6] - Adjusted EBITDA rose by 24.7% to $267.8 million, compared to $214.8 million in the same period last year [6] - Normalized Adjusted Net Income increased by 26.1% to $166.5 million, compared to $132.1 million in Q3 2024 [6] Operating Segments - The company operates in two segments: Market Making and Execution Services [8][9] - Market Making segment includes trading across various asset classes, while Execution Services focuses on agency-based trading and technology services [8][9] Share Repurchase Program - Since the inception of the share repurchase program in November 2020, the company has repurchased approximately 53.8 million shares for about $1.417 billion [15] - The remaining capacity for future purchases under the program is approximately $302.8 million [15] Financial Condition - As of September 30, 2025, Virtu had $755.4 million in cash and cash equivalents, with total long-term debt of $2.0687 billion [14]

Core Points - Eviden has been awarded a €12 million contract by NATO to modernize the communication systems for the Spanish Air and Space Force [1][2] - The project will enhance operations at Air Traffic Control towers across various air bases and is scheduled for completion within 18 months [2][4] - The new communication systems will be mission-critical, operating continuously and supporting various operations, including the transport of key government officials [4][5] Project Details - The modernization project includes the deployment of several hundred civilian and military radio systems at 35 locations, ensuring comprehensive coverage across Spain [2][3] - The communication systems will consist of VHF and UHF equipment, including transmitters, receivers, and management software [3][5] - The systems are designed to remain in service for at least 20 years, with full support provided throughout their lifespan [6] Company Background - Eviden, part of the Atos Group, operates in 36 countries and generates approximately €1 billion in revenue, focusing on advanced computing, cybersecurity, mission-critical systems, and Vision AI [9] - The company has established a strong presence in the defense sector, delivering innovative technological solutions to strategic institutions [7][8] - Atos Group, the parent company, employs around 67,000 people and has an annual revenue of approximately €10 billion, positioning itself as a leader in digital transformation [10]

WAYNE, Pa., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced that the Company has completed enrollment in its Phase 2 LOTUS trial of AVTX-009 in adults with hidradenitis suppurativa (HS). The LOTUS trial exceeded target enrollment of 222 patients with approximately 250 patients enrolled. Topline data from the trial is expected in mid ...

WATERTOWN, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, November 5, 2025 to report its third quarter 2025 financial results and highlight recent corporate developments. To access the live conference call, please register using the au ...

Core Insights - Axogen, Inc. raised its full-year revenue guidance to at least 19% growth, equating to $222.8 million, reflecting strong market performance and operational scaling [1][8]. Financial Performance - Third quarter revenue reached $60.1 million, marking a 23.5% increase year-over-year and a 6.0% increase from the previous quarter [3][6]. - Gross margin improved to 76.6%, up from 74.9% in Q3 2024 and 74.2% in Q2 2025 [6]. - Net income for the quarter was $0.7 million, or $0.01 per share, compared to a net loss of $1.9 million, or $0.04 per share, in Q3 2024 [6][21]. - Adjusted net income was $6.1 million, or $0.12 per share, compared to $3.1 million, or $0.07 per share, in Q3 2024 [6][23]. - Adjusted EBITDA for the quarter was $9.2 million, up from $6.5 million in Q3 2024 [6][23]. Market Developments - The peripheral nerve repair market is maturing, with double-digit growth across all segments, including Extremities, Oral Maxillofacial & Head and Neck, and Breast [3][7]. - New position statements from the American Association of Hand Surgery (AAHS) and the American Society for Reconstructive Microsurgery (ASRM) recognize nerve allografts as a standard medical practice, validating the company's market development strategy [3][7]. - The total number of covered lives for nerve repair has increased to approximately 18.1 million, with coverage among commercial payers exceeding 64% [7]. Regulatory Updates - The FDA accepted the filing of the Biologics License Application (BLA) for Avance Nerve Graft, with approval anticipated by December 5, 2025 [7][8]. Future Outlook - The company expects gross margin for the year to be in the range of 73% to 75%, accounting for one-time costs related to the anticipated BLA approval [8]. - The company reiterates its expectation to be net cash flow positive for the full year [8].

Core Insights - Kirby Corporation reported net earnings of $92.5 million or $1.65 per share for Q3 2025, a 6% increase from $90.0 million or $1.55 per share in Q3 2024 [1][5] - Consolidated revenues for Q3 2025 were $871.2 million, up from $831.1 million in Q3 2024 [1] Segment Performance - **Marine Transportation**: Revenues were $484.9 million, slightly down from $486.1 million in Q3 2024. Operating income decreased to $88.6 million from $99.5 million, with an operating margin of 18.3% compared to 20.5% [3][4][6] - **Inland Marine**: Average barge utilization was in the mid-80% range, impacted by seasonal weather and softer market conditions. Spot market rates declined in the low-to-mid single digits, while term contracts remained flat [2][4][5] - **Coastal Marine**: Strong market fundamentals with barge utilization in the mid to high-90% range. Revenues increased by 13% year-over-year, and operating margins reached around 20% [6][12] - **Distribution and Services**: Revenues rose to $386.2 million from $345.1 million, with operating income increasing to $42.7 million from $30.4 million. Operating margin improved to 11.0% from 8.8% [7][9] Financial Metrics - **EBITDA**: For Q3 2025, EBITDA was $201.4 million, up from $190.5 million in Q3 2024 [11][24] - **Cash Flow**: Net cash provided by operating activities was $227.5 million, with capital expenditures of $67.2 million. Free cash flow for the quarter was $160.3 million [11][32] - **Debt and Liquidity**: Total debt stood at $1,048.9 million, with a debt-to-capitalization ratio of 23.8%. The company had $47.0 million in cash and cash equivalents [11][24] Market Outlook - **Inland Marine**: Expected to see stable market conditions with signs of improvement. Higher barge utilization is anticipated due to seasonal factors [12][15] - **Coastal Marine**: Favorable market fundamentals are expected to continue, with steady customer demand and pricing benefiting from limited vessel availability [12][13] - **Distribution and Services**: Continued strength in power generation and marine repair markets, with full-year revenues expected to rise in the mid-single digits [15][16]

Core Insights - Amarin Corporation has transitioned to a fully partnered commercialization model across all international markets, which is expected to enhance its operational efficiency and market reach [1][3] - The Q3 2025 financial results indicate a positive trend with a 17% increase in total net revenue compared to Q3 2024, driven primarily by strong U.S. sales [4][6] - The company aims to achieve sustainable positive free cash flow by 2026, reflecting confidence in its strategic actions and operational improvements [1][4] Financial Performance - Total net revenue for Q3 2025 was $49.7 million, up from $42.3 million in Q3 2024, marking a 17% increase [4][6] - Product revenue, net increased by 16% to $48.6 million, primarily due to higher U.S. sales, which rose by 34% to $40.9 million [5][7] - Operating expenses decreased by 20% to $33.3 million, largely due to a restructuring plan implemented in June 2025 [9][12] Operating Metrics - The operating loss for Q3 2025 was $11.1 million, significantly improved from a loss of $25.2 million in Q3 2024, reflecting a 56% reduction [4][14] - The net loss for Q3 2025 was $7.7 million, compared to a net loss of $25.1 million in the same quarter of the previous year, indicating a 69% improvement [15][34] - Cash and investments at the end of Q3 2025 totaled $286.6 million, down from $305.7 million in Q3 2024 [15] Strategic Initiatives - The company has established partnerships with seven parties across nearly 100 countries to leverage regional expertise and infrastructure for the commercialization of VASCEPA/VAZKEPA [3][17] - Amarin is focused on enhancing shareholder value through strategic actions and is optimistic about its global business potential [3][4]

MONTREAL, Oct. 29, 2025 (GLOBE NEWSWIRE) -- PyroGenesis Inc. (“PyroGenesis”) (TSX: PYR) (OTCQX: PYRGF) (FRA: 8PY1), the leader in ultra-high temperature processes & engineering innovation, and a plasma-based technology provider to heavy industry & defense, announces today that further to its press release dated October 1, 2025, the Company has completed the first tranche of the Second Unit Group of the previously announced non-brokered private placement (the “Private Placement”) by issuing and selling an ag ...